FDA Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors
Related posts
The Gaza Conflict and its Bioethical Challenges: Rethinking Physicians as Automatic Moral Authorities
As the human tragedy unfolds in Gaza and the surrounding region, characterized by unparalleled levels of destruction and suffering, the plight of hospitals, patients, and healthcare providers has garnered widespread attention in international media. The UN Special Rapporteur on the right to health has emphasized the severity of the situation, stating that “The practice of […]
Academic and Private Partnership to Improve Informed Consent Forms Using a Data Driven Approach
This editorial appears in the April 2024 issue of the American Journal of Bioethics. Informed consent documents are central to the informed consent process and are required for participation in clinical trials in the U.S. The primary purpose of the document is “to assist a prospective subject” in deciding to participate in a research study […]
We Are Not Okay: Moral Injury And a World on Fire
The following editorial can be found in the April 2024 issue of the American Journal of Bioethics. After giving the name “burnout” to the experience of being overworked and undervalued and the physician and patient suffering that comes from it, many clinicians have sought to elucidate further what exactly is wrong with the practice of […]
Qatar’s Bioethics Meeting and A Reply from IAB Organizers
The two following editorials appear in the April 2024 issue of the American Journal of Bioethics. Qatar’s Bioethics Meeting David Magnus What is the purpose of a large academic meeting attended by hundreds or thousands of participants? What are the reasons, given current virtual conferencing technology, to hold such meetings in person? Although there are […]